IA
ZVRA icon

IFP Advisors’s Zevra Therapeutics ZVRA Stock Holding History

IFP Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$36 – 5184
2025
Q4 		$36 Sell
4
-10
-71% -$95 ﹤0.01% 4743
2025
Q3 		$133 Buy
+14
New +$140 ﹤0.01% 4487
2025
Q2 		– Hold
0
– – – 3369
2025
Q1 		– Hold
0
– – – 3939
2024
Q4 		– Hold
0
– – – 4101
2023
Q1 		– Sell
-1,250
Closed -$18K – 4478
2022
Q4 		$18K Sell
1,250
-8,000
-86% -$40.6K ﹤0.01% 2999
2022
Q3 		$134K Hold
9,250
– – ﹤0.01% 1661
2022
Q2 		$134K Hold
9,250
– – ﹤0.01% 1503
2022
Q1 		$134K Buy
9,250
+8,000
+640% +$50.9K ﹤0.01% 1503
2021
Q4 		$11K Hold
1,250
– – ﹤0.01% 2198
2021
Q3 		$12K Hold
1,250
– – ﹤0.01% 2217
2021
Q2 		$16K Sell
1,250
-555
-31% -$5.96K ﹤0.01% 2046
2021
Q1 		$17K Buy
1,805
+555
+44% +$4.85K ﹤0.01% 1915
2020
Q4 		$14K Buy
+1,250
New +$14K ﹤0.01% 1937
2020
Q1 		– Sell
-12
Closed -$66 – 3032
2019
Q4 		$0 Hold
12
– – ﹤0.01% 3157
2019
Q3 		$0 Buy
+12
New +$217 ﹤0.01% 3158

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

IFP Advisors's ZVRA Position: Q1 2026 in Review

IFP Advisors sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 4 shares — an estimated $36 sold.

IFP Advisors first reported a position in ZVRA in Q3 2019 and held it in 13 quarters. The position peaked at $134K in Q3 2022. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • IFP Advisors reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • IFP Advisors sold 4 Zevra Therapeutics shares in Q1 2026, an estimated $36.
  • IFP Advisors first reported a position in Zevra Therapeutics in Q3 2019 and held it in 13 quarters.
  • IFP Advisors's Zevra Therapeutics position peaked at $134K in Q3 2022.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.